Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis.
CONCLUSIONS: TDPs are a preferred first-line treatment for HER2-positive metastatic breast cancer compared with other target agent regimens.
PMID: 29108432 [PubMed - as supplied by publisher]
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Docetaxel | Drugs & Pharmacology | HER2 | Herceptin | Study | Taxotere